Rhinitis
Drug research and approvals for rhinitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 67 studies of rhinitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 67
- Trials authorized in Canada: 24
- FDA orphan approvals: 0
- EU medicines: 9
- A Study to Evaluate Treating Watery Noses With Cryotherapy in the Clinic Setting. This is Cold Therapy, Freezing the…NCT07917091 · Not reported · East and North Hertfordshire NHS Trust · starts Oct 14, 2025
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.NCT07904195 · Phase 3 · Inmunotek S.L. · starts Apr 15, 2026
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.NCT07904052 · Phase 3 · Inmunotek S.L. · starts Feb 24, 2026
- Investigating Nasal and Ocular Immune Response to Conjunctival Allergen ExposureNCT07801625 · Not reported · Dr. Anne Ellis · starts Sep 1, 2026
- Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and…NCT07726147 · Phase 1 · Immunomic Therapeutics, Inc. · starts Jun 20, 2026
- Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisNCT07711262 · Phase 3 · Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · starts Aug 18, 2026
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisNCT07678931 · Phase 3 · Chengdu Kangnuoxing Biopharma,Inc. · starts Aug 13, 2026
- Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish PracticeNCT07651891 · Phase 4 · Karolinska Institutet · starts Aug 1, 2026
- Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With…NCT07588672 · Not applicable · Polyrizon Ltd. · starts Sep 1, 2026
Approved 2
- OmalizumabIg epsilon chain C region inhibitor
- FlunisolideGlucocorticoid receptor agonist
Phase 3 6
- LevocetirizineHistamine H1 receptor antagonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- PseudoephedrineNorepinephrine transporter releasing agent
- DiphenhydramineHistamine H1 receptor antagonist
- Fluticasone furoateGlucocorticoid receptor agonist
- Dropropizine
Phase 2 4
- SB-705498Vanilloid receptor antagonist
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- CetirizineHistamine H1 receptor antagonist
- Fluticasone propionateGlucocorticoid receptor agonist
Phase 1 or earlier 2
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- PhenylephrineAdrenergic receptor alpha-1 agonist
How its trials ended
1,159 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 299 whose ending is known, 70% met their primary endpoint, 7% missed it and 22% stopped early.
- Completed, result not reported65557%
- Met its primary endpoint21018%
- Ongoing11210%
- Status unknown938%
- Stopped: other or unclear343%
- Missed its primary endpoint222%
- Stopped: enrollment or feasibility171%
- Stopped: sponsor or business decision101%
- Stopped: lack of efficacy4<1%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Nov 13, 2026 | Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis or…DM-101PX | Desentum Oy | Pending |
| Dec 31, 2025 | A randomized, double-blind, placebo-controlled, environmental exposure unit trial of intranasal INI-2004 in subjects with ragweed-induced allergic rhinitisINI-2004 | Inimmune Corporation | Closed |
| Oct 23, 2025 | A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab in adult and…Lebrikizumab (LY3650150) / Azelastine | Eli Lilly | Ongoing |
| Aug 26, 2025 | A two-part, adaptive, double-blind, randomized, placebo-controlled, study to assess the appropriate dose and the appropriate dosing frequency of aldp 001 in…Alcaftadine (ALDP001) | Alixer Nexgen Therapeutics Ltd | Closed |
| Jul 30, 2025 | A phase 2, rendomized, double-blind, placebo-controlled study to investigate the safety and efficacy in reducing nasal allergen challenge provoked symptoms of…DM-101PX | Desentum Oy | Closed |
| Dec 22, 2023 | Tezepelumab in the treatment of co-morbid allergic rhinitis and allergic asthma study (TEZARS) - an open-label exploratory mechanistic pilot study to evaluate…Tezspire / Allergen extract standardized dust mite mix/allergen extract… | Kingston General Health Research Institute | Ongoing |
| Oct 19, 2023 | Randomized, double-blind, cross-over clinical trial to assess onset of action and efficacy of azelastine hydrochloride 0.15% nasal spray in the treatment of…Azelastine | Viatris | Closed |
| May 24, 2023 | An open-label, single-dose, three-way crossover study to compare the pharmacokinetics of fixed-dose combination of mometasone + azelastine nasal spray to…Azelastine-mometasone / Azelastine / Mometasone | Sandoz | Closed |
| Nov 30, 2022 | A phase IIIb, single-center, double-blind, two-arms, placebo-controlled, randomized, parallel-group clinical trial to evaluate the efficacy and safety of 2-day…Fexofenadine (M016455) | Opella Healthcare Group SAS | Closed |
| Jul 25, 2022 | A two-part randomized, double-blind, placebo-controlled study to assess the efficacy of the anti-bet v 1 monoclonal antibodies to reduce allergic rhinitis and…REGN5713 / REGN5714 / REGN5715 | Regeneron | Closed |
| Jan 13, 2012 | Desloratadine ActavisDesloratadine · generic | Actavis Group PTC ehf | EMA ↗ |
| Jan 13, 2012 | Desloratadine ratiopharmDesloratadine · generic | Ratiopharm GmbH | EMA ↗ |
| Nov 28, 2011 | DasseltaDesloratadine · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Nov 24, 2011 | Desloratadine TevaDesloratadine · generic | Teva B.V | EMA ↗ |
| Jan 11, 2008 | AvamysFluticasone furoate | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Jul 30, 2007 | AerinazeDesloratadine; pseudoephedrine | Organon N.V. | EMA ↗ |
| Jan 15, 2001 | AeriusDesloratadine | Organon N.V. | EMA ↗ |
| Jan 15, 2001 | NeoclaritynDesloratadine | Organon N.V. | EMA ↗ |
| Jan 15, 2001 | AzomyrDesloratadine | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA